Predicting Treatment Outcomes in Chemotherapy

Weiss, Glen J., et al. Changes in tumor cell-free DNA copy number instability (CNI) predict therapeutic response in metastatic cancers. Cancer Research 76.14 Supplement (2016): 3138-3138.

Gains and losses of chromosomal regions – as a hallmark of cancer – have been detected in plasma as copy number aberrations (CNAs), and for several cancers a relation to tumor size has been reported.

By | May 13th, 2017|Peer-reviewed medical publications|0 Comments

Prostate Cancer Blood Test

Schütz, E., et al. Chromosomal Instability in Cell-Free DNA Is a Serum Biomarker for Prostate Cancer. Clinical Chemistry 2015; 61: 239-248.

Tumor-specific cell free DNA (cfDNA) present in serum and plasma provides a real-time, easily accessible surrogate. We demonstrated variations in the number of cfDNA sequences circulating in the serum of patients with prostate cancer compared with healthy controls.

By | May 12th, 2017|Peer-reviewed medical publications|0 Comments

HPV Genotyping and Treatment Outcome Predictions

Urnovitz, HB et al. Detection of novel HPV mutations and chromosomal number imbalance (CNI) in laryngeal cancer using next-generation sequencing (NGS). J ClinOncol 32:5s, 2014 (suppl; abstr 6072).

The detection of novel HPV mutations and CNI analysis in a single NGS run on HPV-related diseases provides important information into viral-host dynamics while generating biomarkers that can be correlated with treatment outcomes.

By | May 10th, 2017|Peer-reviewed medical publications|0 Comments

Breast Cancer Liquid Biopsy Screening Test

Beck, J. et al. Cell-free DNA copy number variations as a marker for breast cancer in a large study cohort. J ClinOncol 31, 2013 (suppl; abstr 11013).

Using comparative massive parallel sequencing of cfDNA from cancer patients vs. controls, we were able to show that a 16-region model based on CNV, is useful to distinguish patients with breast cancer from matched controls.

By | May 9th, 2017|Peer-reviewed medical publications|0 Comments

Animal Model for MRD in Breast Cancer

Beck, J. et al. Structural variation in mammary carcinomas and their detection in cell-free plasma DNA. PLOS One 2013 (10.1371/journal.pone.0075485).

Mammary tumors are the most frequent cancers in female dogs exhibiting a variety of histopathological differences. There is lack of knowledge about the genomes of these common dog tumors. Five tumors of three different histological subtypes were evaluated.

By | May 8th, 2017|Peer-reviewed medical publications|0 Comments

NGS of prostate cancer

Schütz, E. et al. Comparative analysis of the chromosomal origins of circulating nucleic acids in breast and prostate cancer. J ClinOncol 28:15s, 2010 (suppl; abstr 10505).

The aim of this study was to find signature CNA sequences from patients with breast cancer (BCa) or prostate cancer (PCa) compared to healthy controls, with respect to their predictive potential, as well as to provide new insights into tumor biology.

By | May 6th, 2017|Peer-reviewed medical publications|0 Comments

NGS of cell-free DNA in animals

Gordon, Paul MK, et al. Disease-specific motifs can be identified in circulating nucleic acids from live elk and cattle infected with transmissible spongiform encephalopathies. Nucleic Acids Research 37.2 (2009): 550-556.

In a 25-month time-course experiment, CNAs were isolated from blood samples of 24 elk (Cervuselaphus) orally challenged with chronic wasting disease (CWD) infectious material.Our results may become useful for the early diagnosis of TSE in live elk and cattle.

By | May 4th, 2017|Peer-reviewed medical publications|0 Comments

NGS of cell-free DNA in Healthy Humans

Beck, J. et al. Profile of the circulating DNA in apparently healthy individuals. Clin Chem. 2009; 55: 730-8.

Circulating nucleic acids (CNAs) have been shown to have diagnostic utility in human diseases. The use of mass sequencing and bioinformatics provides the basis for new diagnostic approaches that use CNAs as biomarkers for both malignant and nonmalignant diseases.

By | May 3rd, 2017|Peer-reviewed medical publications|0 Comments

Dr hab. n. med. Jakub Dobruch, FEBU – Liquid Biopsy

Dr hab. n. med. Jakub Dobruch, FEBU. Urological Review, The Polish Association of Urology bimonthly magazine. No. 5/2016

Liquid Biopsy is an example of a new kind of research that could revolutionize cancer detection and treatment of patients affected.

By | November 14th, 2016|Other publications|0 Comments

Advanced Cancer Diagnostics Showcasingat 2016 NCRI Cancer Conference 6-9 November 2016

Chronix Biomedical’s Ireland & UK distributors Advanced Cancer Diagnostics will be attending and showcasing the latest Chronix diagnostic tests: Second Opinion Prostate Cancer Evaluation Test Second Opinion Breast Cancer Evaluation Test Delta Dot Treatment Monitoring Test CNI Cancer Evaluation Test Please visit our booth #79 at The BT Convention Centre, Kings Dock, Waterfront, Liverpool L3 [...]

By | November 3rd, 2016|Events|0 Comments